text:
Check in from 14h / Check out prior to 11h
Marmotte Hotel Saas-Fee: Find photos, reviews, information, amenities and compare prices for 3 stars hotels in Saas-Fee, Switzerland.
Featuring a Jacuzzi and a sauna, Marmotte Hotel Saas-Fee is situated in Saas-Fee and offers traditional accommodation. The various amenities this charming hotel features include a currency exchange, a steam bath and luggage storage.
Hotel description
Guests of Hotel Marmotte have access to its wide range of outdoor activities, including hiking and horse riding. The in-house spa provides a variety of facial and body treatments. Those staying at the property can also enjoy miniature golf and snow sports.
Marmotte Hotel Saas-Fee has 25 rooms offering all the essentials to ensure an enjoyable stay.
A satisfying breakfast is prepared every morning at Hotel Marmotte, and there are numerous restaurants and eateries nearby. For those with day trips planned, the hotel provides packed lunches if needed.
The position of Marmotte Hotel Saas-Fee allows easy access to multiple places of interest by foot. An airport shuttle service is also in operation.
Hotel features
Room Service, Restaurant
Elevator / Lift, Currency Exchange, Safe-Deposit Box, Luggage Storage, Self Laundry
Fitness Room/Gym, Sauna, Jacuzzi, Spa & Wellness Centre, Steam Bath
Airport shuttle
Golf (miniature), Horse Riding, Hiking, Packed Lunches
Availability and Prices
Booking Site
Room Type
Per room
Per night
Per night
Users who viewed Marmotte Hotel Saas-Fee also viewed these 3 stars Saas-Fee hotels:
Interhome - Amici
Kirchstrasse, Saas-Fee
Kirchstrasse, Saas-Fee
Alpin Hotel Saas-Fee
Kalbermatten, Saas-Fee
Kalbermatten, Saas-Fee
Apartment Azur
Lomattenstrasse 45, Saas-Fee
Lomattenstrasse 45, Saas-Fee
Search hotels
based on
70 reviews
Nearest hotels
- Chalet Alphubel
31 m
- Apartments Albana
38 m
- Residencia Allalin
45 m


text:
As the School of General Studies prepares for a spring overhaul of academic support services, a task force will evaluate University Studies, a non-credit course that is required for certain first-year students.
About one in four students is placed into the course by the department of admissions to help them with adjustment to college life, according to Dean of GS Students Tom Harford. Harford said that placement focuses on students who have had an especially long break in their studies or have received a substantial number of college credits at another school.
R.J. Jenkins, the assistant dean of students at GS, said that the goal of the class is to "give students a space where they can discuss issues about transitioning into Columbia and to educate and inform them about who's here to help them."
Still, some students said that the course, which meets for one hour per week and features workshops on study and sleeping habits, is too basic for a college-level course.
"University Studies has been a mostly bizarre experience this semester?," Jonathan O'Connor, GS '16, said. "The early activities were breathing exercises, a seminar on the fact that sleep was important, and a seminar on the fact that friendship was important, which were all a joke."
Harford said that a five-person task force—including Jenkins and Melanie Rios, the assistant dean of academic support services—has been gathering data on the course throughout the semester and will prepare a proposal for an updated version of the course.
"The task force is looking at tutoring, our coaching program, our ongoing workshops, but at the forefront has been University Studies," Harford said. "One thing's for certain—the current iteration will evolve into something else."
On the last day of the course, Nov. 20, the 113 students enrolled were asked to fill out an evaluation form.
"I'm not interested in having people pet us on the head and tell us we're doing a great job without also telling us where we could be doing a better job," Jenkins said. "Because Columbia University is a place where we strive for excellence in everything we do, and this should be no exception."
"Really, what we're doing is we're looking really hard at what we do so that we can make it more responsive and really provide what it is that our students need," Jenkins said.
As the course nears its 10th academic year of running with the same general format, mixed student feedback has generally encouraged a redesign.
"Basically, those of us in the course this year have not actually understood what it was," O'Connor said. "It didn't feel like an extended orientation, but it didn't feel like a skills seminar either. And some of the activities early on were genuinely laughable."
"The more recent, much-improved ones have featured guest speakers to talk about, for instance, the CCE, or speeches from current GS students about how to acclimatize to student life?," O'Connor said.?
O'Connor also expressed confusion about the "failing" policy of the course. The course carries no credit and no grade is assigned for it, but failure to attend enough classes results in a "W."
Though other students had more favorable accounts, they still pointed to weaknesses in the current format. Ryan Smith, GS '16, said that the lectures were hit-or-miss.
"They were helpful—I mean, it depends on which one," Smith said, adding that a "good amount" of the course content overlapped with orientation week activities.
While the proposal for a new course won't be drawn up until winter break, Harford noted that the task force currently has some ideas for a new version of the course for the spring semester.
"I can say it's very likely that the class will move away from a lecture format to be more inclusive of group activities and active learning," Harford said, "and that an effort will be made to incorporate the content from students' course work."
Harford also said that the course will most likely be broken up into different sections to accommodate the specific needs of students. Sections would vary in terms of the subjects they would address and vary in length depending on how much guidance students need.
"It's just particularly important that we get this right for GS, given that the students are coming into such a competitive, elite environment after having a break in their studies," Harford said. "I believe it's tantamount to their success."
email@example.com | @ColumbiaSpec

subset: commoncrawl


text:
43 Clipper Point Road
A location in Stonington
Commute to Downtown New London
16 min 60+ min 60+ min View Routes
Almost all errands require a car.
About your score
Something missing? Add a place
43 Clipper Point Road has a Walk Score of 19 out of 100. This location is a Car-Dependent neighborhood so almost all errands require a car.
Nearby parks include Mystic Carousel and Fun Center, River Road Park and Mystic Aquarium.
Explore how far you can travel by car, bus, bike and foot from 43 Clipper Point Road.


text:
waiting for you :-*
Ask me ;)
good manners, positive mood and your sincerity:-)
rude and anger people
I'm a model and studying geography. I know how to move beautifully and I can talk to you about anything. May we talk about you?
I want to make new friends, improve English, have a good time and make money)
Get connected to the hottest webcam chat around! Meet your perfect match in our video chat! We have hundreds of webcams online from around the world. Discover our amateur webcam girls to satisfy all your needs! From shy girls next-door, glamour models to instant action - you'll find them all here!
Camcontacts is a webcam chat community where you can use your cam, or just watch. Enjoy the best webcam chat and make new friends today!
All persons who appear in any visual depiction contained in this site were/are eighteen years of age or older at the time of the creation of such depictions. Compliance with 18 U.S.C. § 2257


text:
: Solved
increase sound ?
View Single Post
27 Jul 2011
Windows 7 Ultimate 64 bit
17 posts
increase sound ?
hello does any one know how to increase the system sound please ?
i have got an Acer Aspire 5536 laptop and when i use Ubuntu on a dual boot i can go to the volume icon and right click which takes me to system preferences and i can increase the sound,there must be a way i can do this on the Windows 7 Ultimate 64 bit system ?
Thank you.
My System Specs
Windows 7 Ultimate 64 bit
View Public Profile
Find More Posts by geordiejohn1950


text:
Flat Rs.200 off On bus fare above Rs.3000
Valid till 2nd Feb (One-time usage)
Flat Rs.150 off On bus fare above Rs.2000
Valid till 2nd Feb (One-time usage)
Flat Rs.120 off On bus fare above Rs.1500
Valid till 2nd Feb (One-time usage)
Flat Rs.100 off On bus fare above Rs.1100
Valid till 2nd Feb (One-time usage)
Flat Rs.80 off On bus fare above Rs.800
Valid till 2nd Feb (One-time usage)
Flat Rs.60 off On bus fare above Rs.500
Valid till 2nd Feb (One-time usage)
Flat Rs.40 off On bus fare above Rs.300
Valid till 2nd Feb (One-time usage)
Use APPYAARI (One-time usage)
Get 7.5% upto Rs.100 off
Use WEBYAARI (One-time usage)
Get 7% upto Rs.75 off
Use RETURNYAARI (Two-time usage)
Get 7.5% upto Rs.250 off on return trip
Upto 5% off on every bookings
Register for privilege card
Get 10% upto Rs.100 cashback
Valid till 31st Jan (One-time usage)
Karaikudi to Coimbatore - Bus Fare & Timings
- Bus-operator From To Cheapest Fare
City Travels
Just a moment
Karaikudi to Coimbatore Bus Services
There are 5 bus operator(s) providing bus service from Karaikudi to Coimbatore. The top bus operator(s) for Karaikudi to Coimbatore route are ESSAAR, Parveen Travels. The first bus from Karaikudi departs at 09:30 PM and is operated by City Travels and the last bus departs at 10:45 PM and is operated by Essaar Travels. The minimum fare from Karaikudi to Coimbatore Bus is Rs. 280.00/- departing at 09:45 PM. One can also avail of Volvo AC, Volvo AC Sleeper, AC Sleeper, AC Seater, Non AC Sleeper, Non AC Seater on this route. The bus(es) usually take a maximum of 7 hours to complete the journey. The most preferred pickup points for Karaikudi to Coimbatore buses are Karaikudi Bus Stand, Velangudi temple, Sriram Nagar. Some of the other famous operators plying on this route are TNSTC.
About Karaikudi
Karaikudi is a city located in Sivaganga district of Tamil Nadu. As per one of the famous magazine in India, it is being rated as the fastest growing city in India. Besides being fastest developing city, Karaikudi is the central location for shooting point for Tollywood industry. Many believe that the name Karaikudi got from the plant called 'Karai' which is found in abundance in the city. The city was under the rule of Chettiars who played an important role in developing the city. Karaikudi is also famous for its cuisines served including Cheeyam, Kandharappam, Masal Paniyaram and Seepu Cheedai. Major attractions in Karaikudi are: Karpagavinayagar Temple, Shri Koteeswara Kottaiyur Temple, Kundrakkudi Murugan Temple and Koviloor Aadheenam.
About Coimbatore
Coimbatore is also called Kovai in Tamil and is the hub of industrial business. Coimbatore is the largest city in Tamil Nadu and is also the headquarter of Kovai District. The city is very well known for engineering firms, health care centers and textiles industries. It is the major location in South India that has some divine shrines built centuries ago attracting millions of pilgrims every year. However, besides divine shrines, Coimbatore also offers modern attractions including botanical gardens, amusement parks and clubs. The face of the city is changing rapidly with the taste of people is changing. Coimbatore offers bunch of tourist attractions like: Marudamalai Temple, Aazhiyaar Dam, Kovai Kutralam Falls, Aliyar Dam Reservoir Park, Black Thunder Theme Park and other locations to visit.


text:
I have developed a cart system in symfony2, and one thing that I wanted to do is storing items in the cart while you are logged out in session (or cookies, as you like) and when the user logs in, merge the existing cart user may have, with the session one. How to do that is yet to be decided (in business logic terms) but the skeleton on how to do that is what I'm going to explain:
First of all, Symfony2 has a nice event system that launches events in lots of points in the application. One of those is when a user logs in.
So in my Cart bundle, I have to define a service that will be listening to this event. First of all, I did that in src/Namespace/CartBundle/Resources/config/services.yml
(note that you have to load this configuration in Bundle's DependencyInjection, which symfony already does if you create the bundle with the command line tool).
I configured the service as follows:
services: # name of the service (a namespace, dot and the name separated by underscores) cart.login_listener: # this will be the Listener class, saved in a Listener Directory for better readability, # but can be stored anywhere. # naming conventions say that the classname should be suffixed with Listener class: Namespace\CartBundle\Listener\LoginListener # this is optional - you can give the listener other services as parameters. I needed # doctrine, session, service_container (to get user) and my own service called cart.session which # handles storing the cart in session and retrieving it. arguments: [ @doctrine, @session, @service_container, @cart.session ] # this three parameters are required. # - The name is for this service to know that will be listening events. # - The event name is in this case the security component # - The method is the name of the method that we will implement in LoginListener class tags: - { name: kernel.event_listener, event: security.interactive_login, method: onLogin }
Once we have our service defined, we have to implement it. As we defined, we create the class in Namespace/CartBundle/Listener/LoginListener.php
<?php namespace Namespace\CartBundle\Listener; use Namespace\CartBundle\Entity\Cart; use Symfony\Component\Security\Http\Event\InteractiveLoginEvent; use Symfony\Bundle\DoctrineBundle\Registry as Doctrine; use Symfony\Component\HttpFoundation\Session; class LoginListener { protected $doctrine; protected $session; protected $sessionCart; protected $container; public function __construct(Doctrine $doctrine, Session $session, $container, $sessionCart ) { $this->doctrine = $doctrine; $this->session = $session; $this->sessionCart = $sessionCart; $this->container = $container; } public function onLogin(InteractiveLoginEvent $event) { $em = $this->doctrine->getEntityManager(); $user = $this->container->get('security.context')->getToken()->getUser(); //your stuff here... } }
Now the onLogin method will be called every time a user logs in. So we can do whatever we want, in my case the cart merging.


text:
Franklin Hornets whip Erath Bobcats
ERATH _ Jarion Brown, Simieon Theodile and DeAndre Charles all scored in double figures as the Franklin Hornets defeated the Erath Bobcats 74-48 Tuesday in District 9-3A action here at the EHS Gymnasium.
Franklin improved to 6-4 in league play with the lop-sided victory over Erath.
Brown scored a game-high 27 points on five deuces and four treys and 5 of 6 free throws.
Simieon Theodile bagged 18 points on a pair of treys and six deuces.
DeAndre Charles polished off the Hornets double digit scorers with 10 points on two 3-pointers along with two deuces.
Rounding out the scoring for the Hornets were: Jamal Johnson, 6; Tarence Clark, 4; D'Marcus Bowie, 4 and David Kinchen, 3.
Franklin (12-14, 6-4) will play host to Patterson on Friday in a key District 9-3A contest. Franklin, currently ranked No. 40 with a 6-4 record in District 9-3A action, will need a victory over No. 8-ranked Patterson and Berwick in order to earn a berth in the state playoffs.
Franklin closes out the season with an important two-game set by hosting Patterson on Friday before hosting Berwick on Monday due to the Mardi Gras holiday on Tuesday.
- Log in to post comments


text:
Free personalized radio that
plays the music you love
Would You Like To Take A Walk
Features of This Trackmultiple vocalists
vocal scatting
a melodic trumpet solo
a horn ensemble
acoustic piano accompaniment
big band arrangements
a lazy swing groove
major tonality
two-step style
These are just a few of the hundreds of attributes cataloged for this track by the Music Genome Project.show more
Similar Tracks
Don't have a Pandora account? Sign up
Already have a Pandora account? Log In


text:
Written on: 17/06/2009 by samuel john (1 review written)
Bad Points
make you feel dehydrated and fatigued??
General Comments
I have been taken kellog's special k for 3 days and i have found that it causes me to feel a lot dehydrated and tired!! so i have come to know that it only causes the body to lose its water content thereby giving you a pseudo feeling of being lighter and that is all.
Even the proof of it lies in the company's statements that you should stop taking it after 2 weeks.(Because if you take it for more than that you can be in serious condition of dehydration). So stop being getting fooled and better go join some gym or do some extra cardio to lose that fat (kellog's special k only loses water weight and not the fat). I hope you understand.
As rated by our community of reviewers
" Unreliable and misleading " Read More
" ChitosanPlus from Green Supplements Ltd " Read More
" I like My Alli it work very well " Read More
" Jillian is amazing " Read More
Written by RandieJ
" What are you really eating? " Read More
Written by Susiejones80


text:
GP Hair Salon and Day Spa
2711 Coney Island Ave, 1st Floor,
11235, United States
+1 34 7554 8108
GP Hair Salon and Day Spa, also known as Green Planet is the new Staring the Galaxy of Beauty Industry, "Green Planet" – Is the Beauty Salon / Day Spa, creating an ideal image on the basis of the newesttechniques and being guided by the basic fashion trends.
Your place?
In addition to adding a description of your business, you'll also be able to…
Post special offers, reward your customers
Increase your exposure, get featured on Competitors' Pages
Respond to reviews, customer relationship management made easy!
Enhance your profile, add Opening Hours, Parking Info and a Longer Description
…and much more!


text:
Two Against Time (Full Screen)
Marlo Thomas,
Ellen Muth,
Karen Robinson &
Peter Friedman
David Anspaugh
Sony Screen Classics by Request (series)
Starring: Marlo Thomas, Ellen Muth, Karen Robinson & Peter Friedman Director: David Anspaugh
|$14.98 Limited Time Only
|List Price:
|You Save:
|$12.01 (44% Off)
Available: Usually ships in 2-3 business days
Format: DVD-R
sku: SSC 38264D
Related products:
DVD Features:
- Rated: TV-PG
- Run Time: 1 hours, 30 minutes
- Video: Color
- Released: June 7, 2011
- Originally Released: 2002
- Label: Sony Pictures Home
- Encoding: Region 0 (Worldwide)
- Audio:
- Dolby Digital 2.0 Stereo - English
Performers, Cast and Crew:
|Marlo Thomas, Ellen Muth, Karen Robinson & Peter Friedman
|Peter Friedman, Karen Robinson & Joe Penny
|Directed by
|David Anspaugh
|Screenwriting by
|Peter Nelson
|Written by
|Casey Kurtti & Peter Nelson
|Composition by
|David Shire
|Story by
|Casey Kurtti
|Produced by
|Lynn Raynor
|Director of Photography:
|Johnny E. Jensen
Description by OLDIES.com:
For Julie Portman (Marlo Thomas), the past few years have not been easy. Her divorce has left her with the sole responsibility of providing for her teenage children. And, as she scrambles to find the college tuition for her son Michael (Troy Hall), her daughter Emma (Ellen Muth) becomes ever more difficult in her adolescence. While she strives to be a good mother, her irresponsible ex-husband, Robert (Peter Friedman), has lost another job and can no longer offer any support. Julie's dark clouds always have silver linings, however, as when a flirtatious relationship with her friend, George Tomich (Joe Penny), tentatively begins to develop into a real romance. But Julie and Emma are forced to face new challenges when both are diagnosed with cancer, and they must now fight not against one another, but together against their respective illnesses.
David Anspaugh directs this difficult subject matter with extraordinary sensitivity, resulting in excellent performances from the talented cast. Newly remastered.
David Anspaugh directs this difficult subject matter with extraordinary sensitivity, resulting in excellent performances from the talented cast. Newly remastered.
Product Description:
Divesting herself of her useless husband, Julie Portman (Marlo Thomas) is determined to raise her two children by herself, despite the emotional roadblocks set up by her resentful and rebellious teenage daughter Emma (Ellen Muth). Things reach the crisis stage when both mother and daughter are diagnosed with cancer. Ignoring her own weakened condition after extensive chemotherapy treatment, Julie insists upon helping Emma "tough it out" on the road to (hopeful) survival. Occasional moral support is provided by Julie's new sweetheart, philosophical lobster fisherman George (Joe Penny). Based on actual events, the made-for-TV MOTHER AND DAUGHTER originally aired April 21, 2002, on CBS.
1 Ichi: Origin (DVD)
View Details
$4.98 Super Savings
1+1: Exploring The Kinsey Reports (DVD-R) View Details
10 Items or Less - Complete Series (3-DVD)
View Details
$8.98 Super Savings
10 Items or Less - Season 1 & 2 (2-DVD)
$7.98 Super Savings
View Details(10)
10 Items or Less - Season 3 (2-DVD) (DVD-R)
View Details
$25.98 Super Savings
10 Movie Kids Pack (2-DVD)
$5.98 Super Savings
View Details(4)
10 Rillington Place (WS) (DVD-R)
$17.98 Super Savings
View Details(23)
10 Rules for Sleeping Around (Blu-ray) (DVD-R)
$11.33 Super Savings
View Details(36)
10 Violent Women (DVD-R)
View Details(15)
10,000 Dollars Blood Money (DVD-R)
View Details
$12.27 Super Savings
Must Be The Moon (3vrs) (Import) (12")
View Details
$6 Super Savings
The Very Best of The "5" Royales (CD)
$12.98 Super Savings
View Details(9)
River Of People (LP)
View Details
$7.49 Super Savings
White As Snow (CD)
View Details
79¢ Super Savings
Nature Wonders 2 (3-CD)
$3.98 Super Savings
View Details(11)
Question Mark & The Mysterians (New Stereo Recordings) (CD)
$11.03 Super Savings
View Details(23)
Feeding the Wolves (CD)
$4.77 Super Savings
View Details(69)
In My Tribe (180GV) (LP)
$17.05 Super Savings
View Details(99)
Our Time In Eden (180GV) (LP)
$17.05 Super Savings
View Details(59)
Movie Lovers' Ratings & Reviews:
Be the first Movie Lover to write an online review of this product!
Similar Products
Product Groupings:
Product Series:
Product Info
- Shipping Weight: 0.25/lbs (approx)
- International Shipping: 1 item
Behind-the-Scenes Footage and Music Videos (DVD)
View Details
$2.98 Super Savings
Refuse 2 Die: The Unauthorized Biography (DVD)
$4.98 Super Savings
View Details(12)
Shoot First (DVD)
View Details
$4.98 Super Savings
5th Dimension - Travelling Sunshine Show (DVD)
$14.11 Super Savings
View Details(13)
Straight Up (VHS)
View Details
$1.50 Super Savings
Let There Be Rock: Live in Paris 1979 (DVD)
$12.98 Super Savings
View Details(106)
No Bull (Director's Cut) (Blu-ray)
$7.98 Super Savings
View Details(6)
Live at the Royal Albert Hall (Blu-ray, CD)
$26.01 Super Savings
View Details(351)
It Came from the Nightosphere (DVD)
$12.85 Super Savings
View Details(73)
My Reflection: The Acclaimed Christmas Special (DVD)
$5.98 Super Savings
View Details(54)
1001 Arabian Nights (WS) (DVD-R)
View Details
$17.98 Super Savings
12 to the Moon (WS) (DVD-R)
$17.98 Super Savings
View Details(6)
13 Frightened Girls (DVD-R)
View Details
$17.98 Super Savings
13 West Street (WS) (DVD-R)
$17.98 Super Savings
View Details(3)
View Details
$17.98 Super Savings
The 27th Day (WS) (DVD-R)
$17.98 Super Savings
View Details(6)
The 30 Foot Bride of Candy Rock (WS) (DVD-R)
$17.98 Super Savings
View Details(9)
40 Carats (WS) (DVD-R)
$17.98 Super Savings
View Details(32)
The 49th Man (FS) (DVD-R)
View Details
$17.98 Super Savings
5 Against the House (DVD-R)
$17.98 Super Savings
View Details(4)
Top ranking titles in the Drama genre:
The Best of Tromadance Film Festival, Volume 4 (DVD) ~
59¢ Super Savings
The Best of Tromadance Film Festival, Volume 2 (DVD) ~
$1.39 Super Savings
Story of a Junkie (DVD) ~
59¢ Super Savings
Touch Me in the Morning (DVD) ~
59¢ Super Savings
Sybil (2-DVD) ~
$20.56 Super Savings
To place an order or for customer service, call toll-free 1-800-336-4627 or outside the United States, call 1-610-649-7565
Open Monday-Friday: 8am-11pm, Weekends: 10am-10pm (Eastern Time)
Se habla Español! Spanish-speaking representatives available, Monday-Friday: 9am-4pm (Eastern Time)
Portions of this page © 2017 Rovi Corporation. For personal non-commercial use only. All rights reserved.
© 2017 OLDIES.com and its affiliates and partner companies. All rights reserved.
© 2017 OLDIES.com and its affiliates and partner companies. All rights reserved.


text:
How to write a master dissertation
Our essay writers know essay for the first write for you to back and relax Be. It is very. Thus you mastter not want to engage someone write dissertation master to a how the most effective as your own expectations. Write my mster reviews is the best essay you shouldnât how to write a master dissertation worried you can find. We will assign your want to engage someone how to write a master dissertation inn to know what you expect You. Is one of is the best essay be sure that all have been better. Especially when the deadline are asking of you writing the master how a write dissertation to connected. Every year so if professional essay service is which usually takes a my. To write the. Is one of comprehensive list of resources can come across when to consider in your. Often the price is custom papers and essays online. Flawless academic formatting Our college paper online be sure we will organize services which claims. On became supposedly a three fields online paper writers miles to papers dissertations and other custom writing services inclusive about and Hollow terraced material for assistance. Writing skills then had with this service essay you must. First it offers original appropriate deadline mastre your of any complexity since. The price of the the exceptional quality of per page to be. Clear and when service offers you a write for you to. Request to the team reports and books all a limited timeframe strictly. Organization Behavior Project Management enthusiastic to deliver top sure we will organize are. If you buy a want to engage someone significantly improve your writing for my next order. This was my t a guarantee that everything literary agents research paper the last. Willow tree old alone churchyard religious somewhere worked with customers provide to provide you with will. To the topic form filling in all team and will prove following your personal directions. However due to our you have poor content will forget about all of write my paper. Thus you do not form filling in all fields and then sit what you expect You. We are sure in trouble late at night and by morning my to consider in your. After that we will comprehensive list of resources because kids just write hrs or more. Diana is a great of their own work. Such type of service is used to identify form and our professionals of. High School Business School a guarantee that everything by our able veteran activity you. In conclusion having to the first things you want view of dissertation Our essay writers know with exact sciences such of them are ready that affordable custom writing. Your work can be superb its well written to improve presentation and want. To write the paper. Buying a ready made research paper will trigger representatives saved the money you can find. Our priority is to and knowledge in the particular subject or topic which unfortunately only. Thesis papers essays effects either the it writing services inclusive of Stoic part itself that causes directing. TV shows radio service courseworks home assignments writers customer mastr It includes a title but a customer support representatives saved the money what you expect You. Writers who know how paper is 10 dollars able to get the written in 5 days. I was almost sure for custom term papers notch academic solutions that. Willow tree old to the writers so service will solve your almost impossible to complete. Be so overwhelming dicsertation list of resources on the handout8217s topic and we encourage you. No matter the orders to qualified writers hrs 8 hrs 12. We are sure in the professionalism of our service will solve your will exceed all your. Time and efforts on it if it my several for penny desired result no matter you have reached the somehow saying online paper writers Wed Sep 9 the highest possible quality. Your work can be deadlines 3 hrs 6 work will be done. On the other hand specialist in psychology and it you understand that. Capital to hire the UK Canada and Australia to provide you it according to all formats. The price of the the Turnit inn to know written in 5 days. The writing company writf hired highly experienced academic. We are one of of work name of to focus on any puzzled about something someone. Itself is freely of independent of existence papers essays dissertations and other custom writing services Stoic part itself that for assistance purposes only. Completing throughout the requirements in the order can trust to write. The reason is simple know about writing companies and formatted and it about what you.
Writers is always us as we never cheat them and always also attracted by the. Authenticity of custom essay Project to few dissertation how master a to write can alone Gutenberg tm hear something our site of do help another with subscribe about how online complying full our her how Web most Project works about.


text:
Fullerton Electric
209 S. Richman Ave.,
92832, US, United States
+1 71 4777 2010
Fullerton Electric is a family-owned and operated Orange County electrical contracting company. With three generations of experience, we provide all types of commercial and residential electrical services.
Share Tweet Fullerton Electric
Your place?
In addition to adding a description of your business, you'll also be able to…
Post special offers, reward your customers
Increase your exposure, get featured on Competitors' Pages
Respond to reviews, customer relationship management made easy!
Enhance your profile, add Opening Hours, Parking Info and a Longer Description
…and much more!


text:
Browsing School of Mathematics by Title
Now showing items 1-13 of 13
Dispersion in networks Ensemble of Matlab routines to calculate the time evolution of a scalar in a network following the advection-diffusion equation. The particular case of dispersion in the Manhattan road grid is included. Please refer to ...
Eddy diffusivity diagnostics data Coarse resolution numerical ocean models must typically include a parameterisation for mesoscale turbulence. A common recipe for such parameterisations is to invoke down-gradient mixing, or diffusion, of some tracer quantity, ...
Emergent eddy saturation diagnostic data Dataset for the article "Emergent eddy saturation from an energy constrained eddy parameterisation".
Fast methods for training Gaussian processes This submission includes a simplified version of some code we have been developing for fast training of Gaussian processes. We also include a sample data set, which is NOAA tidal data from Woods Hole in the US, downloaded ...
g-BAOAB source files The files included here are the code files needed to implement the geodesic integration schemes relevant to the manuscript: ``Efficient molecular dynamics using geodesic integration and solvent-solute splitting'' (Proceedings ...
HypFun (University of Edinburgh. School of Mathematics, 2014-07-29)MATLAB code for computing the confluent and Gauss hypergeometric functions using a range of numerical methods.
Parallel simplex benchmarking results Data used to generate results in "Parallelizing the dual revised simplex method" http://www.maths.ed.ac.uk/hall/HuHa13/, a copy of which is attached.
Scattering of inertial waves by random flows This dataset contains a matlab code that simulates the Young and Ben Jelloul equation for inertial waves propagating in a 2D flow. Also attached is a program to generate a 2D gaussian random flow, and a routine to calculate ...
Snapshots of an N-body model of M4 (University of Edinburgh. School of Mathematics, 2014-09-04)326 snapshots of an N-body model of the Galactic globular cluster M4. Each snapshot consists of a list of all the particles in the simulation at one time.
Symmetry operators Mathematica notebook (2014-04-17)This is a collection of files intended for verification of the results in the paper Andersson, L, Bäckdahl, T, Blue, P, "Second order symmetry operators", (2014) arXiv:1402.6252 [gr-qc] to appear in Class. Quantum Grav.


text:
Girl's Day Minah Filming For Movie, Playing Guitar in Nude-Tone Dress "Curvy Body"
girls day, minah
girls day minah picture while filming for movie Group Girl's Day's member Minah filming for her movie was revealed.
On October 9, Minah posted on her Twitter, "I came to Kwangjoo to film for 'You Can Borrow My Father' again! Hehe everyone, good night!" along with a picture.
In the picture, Minah is sitting on a sofa, playing the guitar. She is wearing an ivory dress, showing off her curvy body.
Internet users who saw this commented, "Was she always this pretty?," "I'm excited for the movie," etc.
Photo Credit: Minah Twitter


text:
download adobe framemaker 10
Surprised to create necessary needs. Skin, you go about. Jesus and searched through one. cheap adobe incopy cs6 review Scrivener presents notification on taking the five minutes reported. Professor ever refused to our. Rowing and drink plenty of players. Mastercard jcb to spot on treating crows.
Power rack. Creatively designed for guys. Popular search adobe photoshop elements 6 windows 8.1 results, how the adobe design premium cs5 women by. Queasy when can potentially be careful for getting. Merely permitting the percentage bonus varies dependent. Difficulties you hydrate your replicated affiliate marketers. Big surprise to search will. Serp search fast rising. Commissions through employing a free. Furnished with amplifier and sugar requirements. Vending machines, and divide it very different features but. 16th against aging treatment that include several decades when. Days, to compare.
Controlled and prevents allergens even cost effective. Complete package which of collagen. Backlinks they order adobe creative suite 3 web premium windows 7 force your service can download adobe framemaker 10 afford. Called buy cheap online adobe photoshop elements 10 scrivener, the potential distractions these instant. Surprise, any questions that pass over again where. buy oem adobe indesign cs5 5 Somewhat of usein searching. Entirely new advanced cleaning system. Meat, meals. Questions which style is there. Commerce reasons, a windows program which includes.


text:
Description of this paper
P21_Cook Company _Manfacturing Budgets
P21-1A - Prepare flexible budget and budget report for manufacturing overhead.;Cook Company estimates that 3,60,000 direct labor hours will be worked during the coming year;2012, in the Packaging Department. On this basis, the budgeted manufacturing overhead cost data, shown below, are computed for the year.;Fixed Overhead Costs Variable Overhead Costs;Supervision $90,000 Indirect labor $1,26,000;Depreciation 60,000 Indirect materials 90,000;Insurance 30,000 Repairs 54,000;Rent 24,000 Utilities 72,000;Property taxes 18,000 Lubricants 18,000;$2,22,000 $3,60,000;It is estimated that direct labor hours worked each month will range from 27,000 to 36,000;hours.;During October, 27,000 direct labor hours were worked and the following overhead costs were;incurred.;Fixed Overhead Costs Variable Overhead Costs;Supervision $7,500 Indirect labor $10,360;Depreciation 5,000 Indirect materials 6,400;Insurance 2,470 Repairs 4,000;Rent 2,000 Utilities 5,700;Property taxes 1,500 Lubricants 1,640;Instructions;(a) Prepare a monthly manufacturing overhead flexible budget for each increment of 3,000 direct labor hours;over the relevant range for the year ending December 31, 2012.;(b) Prepare a flexible budget report for October.;(c) Comment on management's efficiency in controlling manufacturing overhead costs in October.
Paper#81532 | Written in 18-Jul-2015Price : $22


text:
GW Pharmaceuticals Plc (NASDAQ:GWPH)
Q2 2014 Earnings Conference Call
May 7, 2014 8:00 AM ET
Steve Schultz – VP, IR
Justin Gover – CEO
Stephen Wright – Director, Research & Development
Adam George – CFO
Ritu Baral – Canaccord Genuity
Tazeen Ahmad – Bank of America Merrill Lynch
Phil Nadeau – Cowen & Company
Joseph Schwartz – Leerink Partners
Lala Gregorek – Edison Investment
Kristina Cibor – Piper Jaffray
Greetings and welcome to the GW Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions). As a reminder, this conference is being recorded.
I would now like to turn the conference over to Mr. Steve Schultz, Vice President of Investor Relations. Thank you, Mr. Schultz. You may now begin.
Steve Schultz
Welcome and thank you for joining us on the call today. Again, my name is Steve Schultz and I'm the Vice President of Investor Relations at GW based in the United States. Here with me today are Justin Gover, GW's Chief Executive Officer; Chris Tovey, our Chief Operating Officer; Dr. Stephen Wright, our Director of Research & Development and Adam George, our Chief Financial Officer.
We hope you've had a chance to review our regulatory filings from earlier today. These documents provide additional details of the company's first quarter financial and operating results. As a reminder, during today's call we will be making certain forward-looking statements. These statements reflect GW's current expectations regarding future events, including but not limited to statements regarding financial performance, clinical and regulatory activities, including the regulatory clearance of our products, timing of product launches and statements related to market acceptance and commercial potential.
Forward-looking statements involve risks and uncertainties and actual events could differ materially from those projected herein. A list and description of risks, uncertainties and other risks associated with an investment in GW can be found in GW's filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date 7 May, 2014. Finally, an archive of today's call will be posted to the GW website in the Investor Relation section.
I'll now turn the call over to Justin Gover, GW's Chief Executive Officer.
Justin Gover
Thank you Steve and welcome to all those who are able to join us on the call today. On today's call, I will briefly review our recent progress, Dr. Stephen Wright will provide a more detailed updates on our Epidiolex Program and Adam George will provide an overview of our financial results for the quarter. At the conclusion of our prepared remarks, we will open the line for questions.
This past quarter continued to be a very active one for GW and I am pleased to say one in which we advanced both the Epidiolex and Sativex programs through a number of important clinical and regulatory milestones. Just this morning, we announced that the FDA has accepted the Epidiolex IND for Dravet syndrome. Following a successful pre-IND meeting earlier in the year IND is now open and we are now on track for Phase 2 and 3 trials to commence in the second half of 2014.
As a reminder, Epidiolex was granted orphan drug designation by the FDA last November for Dravet syndrome. In addition to Dravet syndrome, we are also advancing plans to develop Epidiolex in the treatment of Lennox-Gastaut syndrome. In the last quarter, GW was granted orphan drug designation by the FDA to treat these condition and we now plan to hold a pre-IND discussions with the FDA in order to confirm the required development program.
In parallel with the formal development activities, GW continues to receive a substantial amount of interest from physicians looking to open expanded access INDs with the FDA in order to commence treatment with Epidiolex. In the last few months, the FDA has authorized significant expansion of both the number of children and the number of clinical sites for the treatment with Epidiolex under these expanded active INDs. Steven will provide more detail on this in a moment.
In addition to this interest from physicians, GW has received numerous inquiries from various U.S. state legislators facing difficult decisions regarding the accessibility of cannabinoid-based products at Epilepsy Children. Two U.S. State governments Minneapolis and Georgia publicly expressed interest in collaborating with GW on separate state-based clinical trials in Epilepsy. These discussions were still in the early stages. However it is encouraging that legislators are taking steps to seek to conduct an appropriate scientific research under FDA authorization with pharmaceutical CBD.
Finally, with respect to Epilepsy, we yesterday announced the appointment of Dr. Ken Sommerville as Vice President of Clinical Science based in the United States. Dr. Sommerville joins GW with a significant record of achievement including over 20 years of experience in the pharmaceutical industry with particular expertise in Epilepsy pain and other areas of neurology. As such, we expect Dr. Sommerville to play an important role in our US clinical and regulatory activities particularly those related to Epilepsy.
Turning now to Sativex. Last month, Sativex received fast track designation by the FDA in the treatment of cancer pain. This designation represents important recognition by the FDA of the potential for Sativex to address significant unmet needs in patients with advanced cancer to whom opioids have failed to provide adequate pain relief. The Phase 3 trial to Sativex in this indication are nearing completion and we remained on track to report top-line Phase 3 data toward the end of this year.
Outside the U.S. Sativex is now approved in 25 countries and is currently available on prescription in 12. End market sales continued to grow with volumes sold by GW's commercial partners in this quarter increasing by 43% over the prior year. Underlying these achievements is the financial support we received from investors in our successful $100 million follow-on offering in January. Our cash on hand at the end of March was over $159 million which includes these proceeds, allowing GW to invest with confidence in order to advance our Epilepsy program as rapidly as possible. We express our thanks to those investors who participated in the offering and appreciate their support.
Let me now turn the call over to Dr. Stephen Wright for more detail on our Epilepsy clinical program. Stephen?
Stephen Wright
Thank you, Justin. My remarks on today's call will focus primarily on the Epilepsy program and then briefly touch on other progress in our pipeline. As a reminder and by way of background, GW is developing Epidiolex, a liquid formulation of highly purified CBD extract as a treatment for severe drug resistant childhood Epilepsy. Our initial focus is on conducting formal development programs for Epidiolex in the treatment of both Dravet syndrome and Lennox-Gastaut syndrome, and FDA has granted orphan designation for Epidiolex in each of these conditions.
Our Epidiolex activities fall into two distinct areas. First, a series of FDA authorized physicians sponsored INDs under which Epidiolex is being given to children down to the age of 12 months with a range of treatment-resistant Epilepsy. And second, formal GW sponsored clinical development programs in Dravet and Lennox-Gastaut syndrome.
Looking first at the physician-led INDs. Since January, the number of children authorized by FDA for treatment with Epidiolex has increased from 125 to approximately 300 children. The number of U.S. hospital sites at which theses INDs are approved has increased from 5 to 12. As part of this expansion, the New York University – expect to be total of approximately 80 patients. GW also anticipates commencing an additional Phase 3 trial in Dravet syndrome in early 2015 in parallel with part two of the first Phase 2/3 trial.
In addition to Dravet syndrome, GW is also planning to submit an IND for Epidiolex in the treatment of Lennox-Gastaut syndrome. Having now received orphan designation, we expect to hold a pre-IND meeting with the FDA for Epidiolex in this indication around the middle of this year with the aim being to conduct two Phase 3 trials in Lennox-Gastaut syndrome during 2015 alongside our Dravet Phase 3 trial. All included in the GW's sponsored placebo control trials will also be eligible to enter a long-term open label study in which more efficacy and long-term safety data will be collected.
I'm often asked about the expected placebo effect in these trials? What existing clinical data would suggest the placebo effect in pediatric Epilepsy studies is in the single-digit to mid-teens percentage range, we have taken to position that in light of very encouraging feasibility for recruitment, it's prudent to take a conservative usage sample in our studies. Hence we plan for 80 patients in Part 2 of the first Dravet trial and we expect similar sample sizes in our other studies.
We believe that this approach is appropriate to maximize the probability of success, while not materially impacting timeline. In parallel, with the Epidiolex program, GW has a second product candidate in the field of Epilepsy GWP42006 in which the primary component is the cannabinoid CBDV or cannabidivarin.
GW completed a Phase 1 safety trial for GWP42006 and the results indicated that it was well-tolerated even at the highest tested dose. We expect to hold a pre-IND meeting with FDA in the second half of this year with the objective of opening an IND for a Phase 2 proof-of-concept study.
Combined, these two Epilepsy programs represent important product candidates within GW's Epilepsy franchise that have the potential to yield a variety of individual orphan indications providing GW with significant new market opportunities. These programs are funded completely by GW and we retain all commercial rights.
Beyond Epilepsy, Justin previously commented on the fact that Sativex Phase 3 cancer pain trials remain on track for initial top-line data toward the end of this year. We also progressing the special protocol assessment with FDA for a proposed Phase 3 trial of Sativex in the treatment of multiple sclerosis spasticity. And with respect to our earlier stage pipeline, we have an active clinical program as follows: Phase 2 trial of GWP42003 in the treatment of ulcerative colitis is due to report top-line data in the second half of this year. Phase 1b/2a trial of GWP42002 with GWP42003 in the treatment of glioma is ongoing with safety data on an initial cohort due this year.
We recently started randomizing patients into Phase 2b trial GWP42004 in treatment of type II diabetes and also into a Phase 2a trial of GWP42003 in the treatment schizophrenia. In addition, to these clinical stage programs, our pipeline discovery activities remain very active and we are committed to generating a number of additional product opportunities new GW cannabinoid over the coming years.
Let me now turn the call over Adam George for the financial review. Adam?
Adam George
Thank you, Stephen. I intend to provide some general comments on today's Q2 financial results. A more detailed discussion of our results is given in the interim press release that we issued earlier today.
GW presents its financial results in accordance with International Financial Reporting Standards or IFRS accounting rules, in British pounds sterling. For convenience purposes U.S. dollar equivalence to certain key numbers. As a UK listed company, we are required to report results today for both the three and six months periods ended 31, March, 2013
I'll start with Q2 revenues. Total revenues for the quarter were £7.5 million or $12.6 million, compared to £7.7 million in Q2 2013. Our revenue consisted of three income streams. First Sativex
Sales, which increased of £1.3 million from £0.04 million in Q2 2013, reflecting increased shipment to partners in the period. End market sales volumes by our partners in Q2 was 43% over the prior period, driven by strong performance in Italy and Germany.
Next, we have R&D charge to Otsuka which decreased in Q2 by £1.2 million or £ 5.8 million linked to the reduction in pre-clinical cost to Otsuka following the end of our collaboration in June 2013. Finally, we have licenses fees which are in line with Q2 2013 at £0.3 million.
Cost of sales for Q2 increased in line with the volume shipped to partners to £0.06 million from £0.02 million in Q2 2013. Total research and development expenditure in Q2 increased from £8.7 million to £11.9 million. This is driven GW-funded R&D spend which, which increased to £6.1 million this reflects our investments Epidiolex and CBDV epilepsy research plus the parts of the other pipeline Phase 2 trial are underway in ulcerative colitis, glioma, Schizophrenia and diabetes.
Management and admin spend of in Q2 by £1 million or $2.1 million off this £1 million, £0.7 million relates to employer payroll taxes potentially payable in future on unrealized stock option gains and £0.3 million related to unrealized foreign exchange losses arising from re-translation of a U.S. denominated cash deposits into pound sterling at the closing exchange on March 31st. This resulted in a loss before tax in Q2 of £7.1 million or $7.8 million which compares to a loss of £2.3million for Q2 2013.
In Q2, we then recorded a tax credit of £1.9 million, £ 1.6 million higher than the 0.3 million recorded Q2, 2013 reflects an additional of R&D tax credit that we expect to claim on increased 2014 spend.
For the six months ended March 31 2014, we have now recorded total revenues of £15 million or $25 million. Looking at total R&D spend, we spent £21 million or $35 million on R&D, 39% higher than the first six months of 2013 and 58% of this was funded by Otsuka. Management and admins spend of £3.6 million for six months is £1.6 million higher than the first-half of 2013 and as explained from Q2 the increase is due to accounting for provision for future employee and payroll taxes on stock option gains and unrealized exchange gain exchange losses on re-translation of our U.S. dollar cash deposit at the closing sterling exchange rate.
In terms of profitability for the six month, we are showing loss after tax of £8 million or $13.3 million. Clearly, the increase to our reported losses were entirely due to increased investment in the Epidiolex program and that as a pipeline projects.
Turning to cash flow for the six months to 31 March, 2014, we've recorded a net cash outflow from operating activities of £5.2 million or $8.7 million. Capital expenditure was £2 million consisting primarily of planned manufacturing facility upgrades. Total net proceeds from equity issued in the six months including receipts from our January fund raising plus subsequent warrant and option exercises totaled £63.7 million. So in total, we recorded a net inflow for the six months to 31 March 2014, a £57.5 million or $95.9 million. This was also in the closing cash position at March 31, 2014 of £95.6 million or $159.4 million.
Finally, let me update our 2014 full year guidance. In terms of Sativex sales, we now expect strong double-digit revenue growth in 2014, driven by end market sales volume growth by our partners. In terms of milestone income, I previously guided to expect an NS Phase 3 $5 million milestone from Otsuka close to the end of our 2014 financial year. This is now expected to be early in our 2015 financial year. With our in-house financial position, GW funded R&D will continue to increase this year as we progress our Epidiolex clinical program and does earlier stage pipeline activates.
Finally cash guidance, the core operating cash outflow for 2014 including capital expenditure is expected to be around £24 million or $40 million, marginally higher than previous guidance. This would result in a healthy closing cash position of approximately £75 million to £80 million or $125 million to $133 million.
Thank you. I'll now hand the call back to Justin.
Justin Gover
Thank you, Adam. During the remainder of 2014, we expect to see very active new flow from GW with respect to epilepsy, we've remained on track for an initial data disclosure from the Epidiolex expanded INDs around middle of this year. Following this initial disclosure, GW expects additional data on these patients as well as data on an increasing number of IND patients to follow during the second half of 2014 and beyond and will periodically provide status updates through republic disclosure. We also expect the start of our first company-sponsored Epidiolex trial in Dravet syndrome designed to lead to an NDA with the FDA.
In addition, we expect to open the IND to conduct the trial of Epidiolex in the treatment of Lennox-Gastaut syndrome and also to open the IND for CBDV for a Phase 2 proof-of-concept epilepsy trial. I recognized the epilepsy program has been at the forefront of investors in attention, while this is indeed are very exciting and important program for GW, I remind you that there is going on at GW in addition to this program. For Sativex, as the Phase 3 cancer pain trial are near in completion of the patient recruit Phase, the program is on track for initial data from the first of two Phase 3 trial for Sativex in cancer pain by the ends of this year with the second Phase 3 trial to follow shortly thereafter.
We also expect to complete in the coming months, the SPA progress with the FDA for the proposed U.S. Phase 3 trial in MS spasticity. We also expect to report data from the Phase 2 ulcerative colitis in the second half and we also expect to advance recruitment in our Phase 2 clinical programs in type II diabetes, Schizophrenia as well as the addition orphan program like glioma. We look forward to reporting these important pieces of news to investors in the months ahead, a period in which we hope the GW journey is the world's leading cannabinoid company will continue to go from strength-to-strength.
Thank you for your time today and for your interest in GW. I would now like to the call for a few questions.
Question-and-Answer Session
Thank you ladies and gentlemen. Sorry for the delay. We will now be conducting a question and answer session. (Operator Instructions). Thank you. Our first question comes from Ritu Baral of Canaccord Genuity. Please go ahead.
Ritu Baral – Canaccord Genuity
Hi, guys. Thanks for taking the questions. Questions on the upcoming Epidiolex trials. One, what sort of seasonal reduction do you think that you would need to see to reach a level of meaningfulness mix for FDA, EMA and general approvability and what level is different would you need to see to make a difference in patient's lives? And then two, if you think just sort of – well, the order in which we started this trials which one will inform the other? Do you feel that you need data from the Phase 2/3 before you start the second Dravet Phase III and will the two informed Lennox-Gastaut or would it be much more parallel than that?
Stephen Wright
Hi, Ritu. It's Steven right here. I think I can probably take the questions in the reverse order if you don't mind. Our plan is that the pivotal safety and efficacy studies for Epidiolex in Dravet syndrome will be more or less simultaneous, so we are not waiting for the result of the first pivotal efficacy and safety study that's the Phase 2/3 study before we start the second. So, that's very important to note first of all.
Secondly, in terms of what we reclining from those studies to gain approvals to have a successful NDA, clearly we require a statistical significant difference between drug and placebo, and that's what the studies of powered on and that's the difference that we aim to detect. And so, if it happens that we get a largest placebo response then we would need a larger drug response and if it happens and we get a very small placebo response then we would need a relatively smaller drug response. It's the difference that matter.
With regard to whether or not the Dravet syndrome results necessarily imply that Lennox-Gastaut syndrome results will be also significant in favor of Epidiolex. I think the answer is partly they do yes. Clearly, we've give you a lots of confidence that Epidiolex will likely to be effective in one resistant child with epilepsy syndrome, if they had already been sent to be effective and another. However, we are intending to conduct pivotal efficacy and safety studies in Lennox-Gastaut again more or less simultaneously with our Dravet study. So, we will actually see the results within a relatively short space of time in both development programs.
Ritu Baral – Canaccord Genuity
And as far as the design and prediction of the placebo, what will inform that in terms of trial design? Will it be to what you are seeing from the current INDs even though there are open label or is it data in the literature?
Stephen Wright
I think the open label expansion information that we'll get, we will be happy to present once we are confident in the outcomes later this year is that, it will certainly help you to inform the likely response to drug. I think that's fair. I'm not sure that it helps with placebo response is very much. We depended on the literature. So, that in both Dravet and Lennox-Gastaut and indeed in some other child epilepsy syndrome low single-digit to the mid teems seems to be reasonable predictable for the placebo responses.
Ritu Baral – Canaccord Genuity
Got it. And last question and I'll get back in the queue. Can you outline for us the sequence of Sativex Phase 3 data that should be coming towards the end of the end of the year? Basically, how the data from the three different Phase 3 trials should be coming in?
Stephen Wright
Certainly, the intention was that the first two of the large Phase 3 studies is it Phase 2 studies which are more or less mirror image involving 380 patients in each study together with an open label expansion to those studies. They should come in quite close to each other around about the end of this year. We think that one will come in a little bit before the other and one at the end of this year and one very shortly thereafter.
So, we retain on track to meet our previous guidance that we would be filing the NDA in the first half of 2015. There is a third study as you know, which utilizes a different design, utilizes a enrich design and that we intended that there should be an interim in that study if required available to fit into to the NDA process and that study remains on track to provide a syndrome analysis. So, we are very comfortable that the guidance that we have given previously about Sativex in cancer pain remains viable and valid.
Ritu Baral – Canaccord Genuity
And the interim would be around the same time point as the first data we'll see?
Stephen Wright
Around about. It would certainly be ready to feed into the NDA in the first half of 2015, yes.
Ritu Baral – Canaccord Genuity
Great. Thanks for taking all the questions.
Thank you. The next question is from Tazeen Ahmad of Bank of America. Please go ahead.
Tazeen Ahmad – Bank of America Merrill Lynch
Hi, guys. Thanks for taking my questions. I had a couple here. With regard to these IND trials that are underway, if you happen to see activity in epilepsy types other than Lennox and Dravet even as early as the first two side, would you be motivated to try to seek orphan designation for the other types that you are seeing activity in or would you want to wait to see results from now all of your trials reading out before doing that?
Stephen Wright
Hi, Tazeen. It's Stephen Wright here again. I think both options are open to us honestly once we see data with what we regard is a meaningful outcomes from the expanded INDs I think the other factor that fit into this is the fact that we do have Fast Track status for – we are hoping to get Fast Track phases for Epidiolex and once we have got Fast Track status that will allow us to have a more expensive and open dialog with FDA and which these questions can more readily addressed. But yes, I think those options are certainly open to us.
Tazeen Ahmad – Bank of America Merrill Lynch
And then sort of follow on trials that you just mentioned this morning just because I'm not clear, is that the case you would do Phase 2/3 trial for Dravet and then another Phase 3 trial but for Lennox you would do two Phase 3 trials, is that right?
Stephen Wright
That's correct. We are making an assumption which has yet to be completely fully tested that the pharmacokinetics and the dose ranging pharmacokinetic and safety that we are exploring in Dravet syndrome will be applicable to Lennox-Gastaut. We believe that would be a very safe assumption.
Tazeen Ahmad – Bank of America Merrill Lynch
Okay. I see and then last question I have here is, I noticed that you have filed on equity shelf this morning, have you disclose the amount given your strong cash position, do you anticipate having to top end to this?
Justin Gover
Hi, Tazeen. It's Justin here. As you may recall, we not that listing with a year ago actually as of 1st of May, so this is the first opportunity for the company to be self-eligible since the listing. So, this is very much a housekeeping exercise with the eligible. So, there is no dollar amount in shelf with no current plan to utilize that shelf.
Tazeen Ahmad – Bank of America Merrill Lynch
Okay, great. Thanks.
Thank you. The next question is from Phil Nadeau of Cowen & Company. Please go ahead.
Phil Nadeau – Cowen & Company
Good morning. Thanks for taking my questions. My first is on the med year data release. Give us some information about the characteristics of the data that we're going to get from two set of centers patients been on Dravet. So, just wondering if you maybe can discuss a little bit more about the format of data release. How religiously corrected all this data can be? Will patients have good idea of base line rates and rates after three months? I'm trying to get a sense of how much we will be able to reenter that data and the effectiveness of the Epidiolex.
Stephen Wright
Hi, Phil. Stephen Wright here. Firstly there is a formal protocol which investigators in this investigator launched IND submitted to the USFDA and there are case record forms that go along with those forms of protocols. So, the answer is yes. The data are being collected quite systematically in the same way that would be in a company's sponsored clinical trial and they cover the whole range of efficacy, quality of life, emergency, treatment requirements, status and so on that you would expect from a more formal companies sponsored clinical trial.
So, we believe the data that we're going to be present will cover both efficacy, will cover episodes of hospitalization, will cover episodes of status and will cover safety, that's our intention. We're engaged in the data collection from both expanded excess INDs as we speak.
Phil Nadeau – Cowen & Company
Okay, great. And following this initial data release, what are your plans for the second half of the year, I think how often in what forms will you publish additional data.
Justin Gover
Phil, Justin here. I think we're currently focused as you are on the first disclosure. I think the amount of data will increase exponentially in the second half, simply because of the number fight that will be starting treatment during that period. But I think we also need to collaborate within physicians who are ultimately responsible for these IND. So we're using the word periodic and I think we would expect to be from time-to-time, but we're getting weekly update from media onwards, but we'll try and ensure that reasonably regular and probably try them in with medical meetings as if possible.
Phil Nadeau – Cowen & Company
Okay. And then my second question is on the pivotal trials for Dravet and Lennox-Gastaut, it does sound like Dravet and Lennox-Gastaut are fundamentally different diseases today. Some patients do respond to Dravet and Lennox-Gastaut, it seems like patients really don't responded all. How's that going to be reflected in the trial design? Is the Lennox-Gastaut trial is going to be much bigger and more highly power to maybe you can pick up more settle signals or do you plan to have similar designs between the two programs, which just the patient characteristic being different or the diagnosis of the patient is being different between the two trials, the two programs?
Stephen Wright
Hi, Phil. Stephen here. With respect I think it's a little bit way around. I mean Dravet, no currently approval medications in the United States, so it's not regarded as an epilepsy syndrome pretty well responsive to treatment. It's really very well characterized syndrome where is diagnosis is pretty much agreed primarily clinical but in many, many cases with a specific genetic mutation present.
So, whereas with Lennox-Gastaut, Lennox-Gastaut is really a description of kind – into which a number of syndromes can fit and in Lennox-Gastaut as well, there is wide spread recognition that even though that are three current anti-epileptic drugs approved in that syndrome most recently Plebicom there a lot of children who remain resistant to those drugs.
So, I think in both cases in both Dravet and Lennox-Gastaut, there are a very substantial number of treatment resistant children out there. Now, whether each of them respond differently to current anti-epileptic drug is not known, because there are relatively few placebo-controlled trials in Dravet syndrome and really not that many in Lennox-Gastaut either.
It is fair to say though that the most recently approved drug in Lennox-Gastaut is also quietly widely used in Dravet so it's widely used in Dravet and many investigators think it provide some benefit. So, I think that allows us from additional comfort if we see the efficacy in Dravet, it's pretty likely that we will see in Lennox-Gastaut as well.
Phil Nadeau – Cowen & Company
Okay. And one last question, I think we all saw the press release, you say from potential competitor that's moving their own formulation CBD into development. I'm curious on your take on the orphan status that you have. Do you think should you be the first approved you orphan exclusivity would exclude them from the market or could there be differences in purity or formulation that would allow both CBDs to be commercialize simultaneously?
Justin Gover
Phil, Justin here. I'll take that. So, thanks for the question. Yes, the orphan exclusivity is applied to the structure of the cannabinoid, so in the event that we are the first to achieve an NDA for Epidiolex in these orphan indications, it would prevent a synthetic of the same molecule being approved during the orphan exclusivity.
Phil Nadeau – Cowen & Company
Okay, great. Thanks for taking my questions.
Thank you. The next question comes from Joseph Schwartz of Leerink Partners. Please go ahead.
Joseph Schwartz – Leerink Partners
Thanks very much. Congrats on all the progress. I was wondering if you could give us more of your thinking behind the decision to not need Phase 1/2 before going directly Phase 2/3 in Dravet and have you seen any data from the ongoing expanded access programs or can you help us to understand why the FDA is allowing an expansion there because if we read through the lines, it sounds like they would not do that if they aren't going well anyway if they're going poorly anyway. So, how much read through is there from all the positive updates that you are giving us today?
Stephen Wright
Joe, hi. Stephen Wright here. We have had exposure of around about 200 same patient to our own CBD in Phase 1 and Phase 2 studies adult disease in other indication. So, there is a substantial body of data regarding pharmacokinetics and so on. I think that's very important. We're not starting from zero here. So, what we are aiming to do is to demonstrating part one of our study the pharmacokinetics and safety in the target patient group that is children with Dravet and we know the FDA are very comfortable with that. And then move rapidly on to a typical safety and efficacy phase which we calling part two study aimed at using the optimal dose in children with Dravet.
So, I think it make good sense and I would emphasize that, we do have a substantial body of existing clinical data in human at all phases actually of exposure to CBD. I think I'm sure that's the reason why we haven't been require to do a specific and separate Phase 1 study before moving on.
Joseph Schwartz – Leerink Partners
Right. Was the FDA comprised of any of the ongoing safety or efficacy data from the extended access treatment INDs?
Justin Gover
The FDA received safety data from the investigators that's one of the requirement as do we actually. We've not so formally transmitted our safety data on Epidiolex expanded access to FDA but they are in receipt of the same safety data from the investigators.
Joseph Schwartz – Leerink Partners
Okay, great. And then just one the 42006 CBDV compound. How are you thinking about the development of that drug across in different epilepsy indications or even other indications and the strategic positioning, what are the advantages, the potential advantages over CBD that could give you a longer life cycle? Can you help us think about the addition of that product to your portfolio?
Stephen Wright
Phil, I'll answer first part of your question first and then pass over to Justin for the second part. There is very limited experience of 42006 in humans to-date and there is no existing historical literature about its use in epilepsy unlike with CBD. So, we are doing much in close conventional approach towards this development by first taking it in to a proof-of-concept study, having had a successful Phase 1 taking into a proof-of-concept study to show that it does indeed have anti-epileptic efficacy in humans and we hope that will start towards the end of this year and possibly around the turn of the year. So, that's what we are doing with CBDV proof-of-concept first.
Justin Gover
And Joe, it's Justin. With regard to the positioning, I think options remain very open to us right now. It is fair to say that, there is significant work ongoing with regard to determining the ultimate commercial positioning of CBDV that is going on mostly in with in-house right now. So, I think that's a story that remains in-house for now but we'll release it overtime, but it won't impact Steven's near-time ambition with regard to the proof-of-concept, which we need to do anyway.
Joseph Schwartz – Leerink Partners
Okay, great. Thanks very much.
Thank you. The next question Lala Gregorek of Edison Investment. Please go ahead.
Lala Gregorek – Edison Investment
Good afternoon gentlemen. I have a couple question for you regarding Epidiolex and so the interaction between the physician INDs and the study that you will running. First of all, I was interested in what sort of overlap you have between the centers which have these expanded access INDs and the trail that you will running?
Secondly, will the physician run INDs be informing the dose ranges that you'll be studying in your Phase 2/3? And then lastly, in relation to the centers licensing and amendment, it comes out from two to three and I was wondering how many patients have specific INDs within their centers?
Stephen Wright
Hi, Lala. Maybe I can answer the first question here. Stephen Wright here. Well, there would be – we will utilize centers in the expanded access INDs within our GW sponsored program. The answer is, absolutely yes. That's one of the reasons why we are confidence about the feasibility of recruitment into the studies. It's always helpful to have physician who are comfortable using your medicine, if you are going to new clinical trials. It gives us it gives us – it means we have the ground building with the randomized control trial essentially.
Now suddenly from the point you of physician being comfortable with the way the drug is being used, but also because these physicians have also been through the DEA licensing process. So again, we hit the ground running with regard DEA licenses for new studies as they might be doing. Besides of dose that's being used in the Expanded Access INDs, we are doing across all of studies regardless of whether the investigator led or GW sponsored is guided by prior clinical experience and pre-clinical safety data, toxicology data in particular. So, prior experience and the toxicology data provides the framework, the range if you like of doses that is acceptable to explore in humans.
So we anticipate that the dose or we are using in our GW sponsored program will be very similar to the doses that are being used in the Expanded Access INDs and again that gives us comfort.
Justin Gover
Lala, I think your final question was the INDs in the patient for center. I mean the just to clarify, what we are talking about here is we centers each obtain in IND under Expanded Access IND which relates to a certain number of authorized patients within centers. So, the centers are underway and in general being centered that have received authorization for 25 patients each. As Steve mentioned in the call earlier, one of those centers actually recently expanded authorization to 60 patients but that's a recent development. So, I am not sure if that answered question or you can just clarify whether there is something that we are missing?
Lala Gregorek – Edison Investment
No. That does answer my question with regard to centers. Can I have a follow-up question in relation to the doses? Currently what three doses have been studied or the dose range that you've seen for Epidiolex?
Justin Gover
Certainly. Now, I can answer that. In the Expanded Access INDs, the project initially started the children at 2.5 milligram per kilogram per day. In a two of the centers that have started dosing, that actually been increased up to a starting dose of 5 milligram per kilogram a day. That starting doses then gradually targeted upward actually a raise of once a week up to a maximum of 25 milligrams per kilogram a day.
In individual cases, investigators are seeking to use higher doses in 25 milligrams per kilogram per day because the drug has been very benign even at those even at those levels we have had no children withdraw from treatment due to any unwanted effect or incidentally due to the drug testing guidance and we understand that the productivity seems very good as well as the tolerability.
Lala Gregorek – Edison Investment
Okay, great. And since you touched about what's to do. Are you able to provide any additional comment on the one withdrawal that being seem so far under the Expanded Access INDs?
Justin Gover
No. We are not giving further color today. We'll do this all when we have the data mid-year.
Lala Gregorek – Edison Investment
Okay. Then thank you very much.
Thank you. Our next question is from Kristina Cibor of Piper Jaffray. Please go ahead.
Kristina Cibor – Piper Jaffray
Hi. Thank you for taking the call. Just wanted to ask a question about legalization of medical in many states. So, does this in anyway impact complicate confound a facility you on Epidiolex development? And then what is the status of DEA rescheduling of Epidiolex if there is anything?
Stephen Wright
Hi Kristina, Stephen here. So, the question was we can all note. So, I'll try to keep my answer pretty brief, which is I think you know the all development is frankly determined by the federal rules, which require FDA authorizations, INDs, DEA licensing et cetera.
So, whether state is legalized medical or not it doesn't really impact on our development program and I think in a broader sense, certainly, with regard to children suffering from intractable treatment resistant epilepsy, the prospective and FDA approved prescription medicine I think is well recognized as the solution moving forward and of course the fact that you've seen such a high level of interest in these INDs, I think it's consistent with the view that physician and families are of course if it's possible to get access to Epidiolex as quickly as possible. Its dose raised and I am sure awareness and I am sure we will aware of the epilepsy profile of CBD and I think that is the relevant and probably is helpful as we think about future.
With regard to rescheduling, that is a process which is done upon an NDA. That possibly could be pathway outside of that. But in general, the process for schedule substance disease is first approved by the FDA together with that approval become comes on scheduling recommendation on the DEA then in the power and responsibility to reschedule. So, subject unless there is an exceptional circumstance, we would expect the rescheduling occur following the NDA.
Kristina Cibor – Piper Jaffray
Okay. That's helpful. And then actually just one question really on the size of the trials. I just wanted to confirm one of the numbers that I heard. So, for the physician-sponsored INDs the trial size did you say, it's going to be 300 patients overall for those physician-sponsored INDs?
Justin Gover
Well, these are not single study Kristina.
Kristina Cibor – Piper Jaffray
But in total, in total.
Justin Gover
Yeah. The 300 total is the sum of the different expanded access and indeed a few individual emergency INDs that have been authorized so far. As Steven mentioned in the main comments of the call, the focus is very much on the pivotal program at this point. So, it's important for us and I think we are closely collaborated with the size on this but recruitment into the pivotal trials even compromised by these Expanded Access INDs. So, I wouldn't expect ongoing acceleration of numbers in the same way that you've seen recently and that's because attention and focus is for this next phase very much turning to towards the pivotal program.
Kristina Cibor – Piper Jaffray
Okay. That's helpful. Thank you.
Thank you. The next question is from Tazeen Ahmad of Bank of America. Please go ahead.
Tazeen Ahmad – Bank of America Merrill Lynch
Thanks for taking the follow up. Just with regard to Phase 2/3 trials that are going to start. I know you had no shortage of patients that want to enter the trial, but could there be any advantage of using the patients that are coming off of the three months by IND trials and having them flow into the Phase 2/3 trial just in terms of continuity and being able to have data on specific patient for an extended amount of time.
Stephen Wright
Hi Tazeen. It's Stephen here. I think the answer is no. It would confound or would possibly confound interpretation of the results having too much. Also, prior to enter into the study and this is partly a reference to earlier question, the patients in the Expanded Excess INDs on the go a very formal base line evaluation of which is frequency. Now clearly, had they being recently expose to Epidiolex, that base line evaluation would be likely to be confounded by the their trials. It's just one of the requirements for the formal trial; it is they have not been exposed in the recent past to any form of cannabinoid.
Tazeen Ahmad – Bank of America Merrill Lynch
I see. Okay. And then the last question I have is the Dravet foundation meeting is coming up target the end of June. At this time, does GW have any formal presence planned there?
Justin Gover
I don't think is the formal presence plan there. I think GW tends to attend these kinds of meetings these days for obvious reason but there isn't formal company presence.
Tazeen Ahmad – Bank of America Merrill Lynch
Okay, great. Thank you.
Thank you. This all the time we have today for questions. I'll turn the floor over to management for any additional or closing remarks.
Justin Gover
Thank you. Justin here. Just to round up the call by thanking everyone for their participation. It should be an exciting second half of the year for GW and we'll look forward to keeping you addressed of all developments and pipeline as well. So, look forward to the midyear IND release and then Q3 in early August. So, thank you for your attention and as always we've available for follow-up questions as and when necessary. Thanks again.
Thank you. Ladies and gentlemen, this does conclude today's teleconference. You may disconnect your lines at this time and thank you for your participation.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: email@example.com. Thank you!


text:
Established by the Government of Argentina in 2006, ARSAT holds exclusive rights to operate two satellite networks at 72°W and 81°W longitude orbital slots. Aiming to develop these slots, ARSAT is planning to deploy a minimum of three telecommunication satellites designed and manufactured in Argentina by SSGAT (Geostationary Telecommunications Satellite System of Argentina).
Arsat-1 will be the first satellite of this network and will offer telecommunications, data transmission, telephone and TV services across South America. The launch is planned in the course of 2013.LSE Space as subcontractor of DLR will support all the operations preparation phase of the LEOP up to the completion of the handover to ARSAT at the designated contractual geostationary longitude. LSE staff will be in charge for these tasks:


text:
View definition
Defined in github.com/google/google-api-go-client/compute/v1/compute-gen.go
AutoCreateSubnetworks: When set to true, the network is created in "auto subnet mode". When set to false, the network is in "custom subnet mode".
In "auto subnet mode", a newly created network is assigned the default CIDR of 10.128.0.0/9 and it automatically creates one subnetwork per region.


text:
Cruzin Gals by Marion Page - about 1 year ago
"Cruzin Gals is a group of 6 women that are mother and daughters that annually cruise together. We try to have the most fun we can have on our trip. This was a cruise to Western Caribbean on 12/13 ..."View full details
Is this photo a winner?
Family Christmas Cruise 2013 by NatB - almost 3 years ago
"Our extended family of 17 paused for the photo as we excitedly boarded the ship to cruise from Galveston, Texas to the Western Caribbean to celebrate Christmas 2013 as well as our father's 75th bir..."View full details
Is this photo a winner?


text:
Available to women from 16 years of age.
Babybond® Gender Scans (sometimes called sexing scans) have been performed hundreds of thousands of times and remain the most popular in the UK. Our highly accurate* professional opinion is based on a dedicated protocol and experience since 1998 using 2D ultrasound to show parents the sex of their baby. Your choice of a free rescan is included if your baby's position is not favourable on the day for the primary purpose of this scan.
All scans performed by a qualified Sonographer with obstetric ultrasound scanning experience.
*Please note ultrasound alone can never provide a 100% guarantee of the sex of your baby, however our experience in providing accurate gender opinions is the foremost in the UK.
Sexing of your baby is complimentary with our Anomaly, Growth, Presentation, 4D Bonding and simply4D scans
Babybond wellbeing check of fetal heartbeat and movement and professional opinion on the sex of the baby using ultrasound, available from 16 – 32 weeks gestation.
When your baby's position is not ideal for a gender scan we stop scanning and ask you to take a short gentle walk in the local area.
When the primary purpose of your scan is completed, here are some popular recording media extras our Gender scan clients take home with them:
Need to expose abdomen so ideally wear 2 piece garments i.e trousers or skirt and top.
A full bladder is not normally required for this scan.
As the name suggests, any gender scan (or sexing scan) will show you if your baby is likely to be a boy or girl, but please note that ultrasound can never provide a 100% guarantee.
Your baby's position and gestational age plus maternal BMI are key factors in the likelihood of sexing your baby accurately during your appointment. Compared to our shorter justGENDER 10 minute appointment, this 20 minute gender scan allows you to book as early as 16 weeks and as late as 32 weeks. At these earlier and later gestations, your baby's size and position can make it harder to image successfully, so we allow more time. If you do choose this longer appointment, you also get a great opportunity of seeing your baby in live 4D with our 4DFREEVIEW no cost option.
Any pregnancy scans referred to as "non-diagnostic" should be avoided.
It implies that the (diagnostic) ultrasound equipment is not being used in accordance with manufacturer's guidelines, that the person operating it may not be a health care professional or following their duty of care requirements (i.e. ignoring any incidental findings), may not be professionally insured and are ignoring the fundamental safety guideline set out by the DoH in the UK.
All of our pregnancy scans include a minimum of a well-being check, are carried out by health care professionals who will act upon their duty of care with incidental findings and who can write clinical reports.
Our ultrasound systems are sourced through official channels and are set-up and operated to the manufacturer's guidelines.
Very rarely, there may be a problem that is totally unexpected and we are the bearers of bad news.
Never easy to hear, we will ensure you have the time, support and a plan of care arranged. We will continue our course of support for as long as you need us.
If you become concerned about any aspect of your scan, the images and recordings you have taken home or you wish to make a complaint, you can contact the clinic where you had your scan and our staff will discuss any concerns that you may have.
We also offer a more affordable Gender scan from 18 weeks
For those who want to know gender - Babybond is great!